Perimeter Medical Imaging has received a $7.44mi grant from Cancer Prevention and Research Institute of Texas (CPRIT) for the further development of its artificial intelligence (AI)-based OTIS technology.
The sponsored technology is designed to provide real-time information during breast cancer surgery. It enables surgeons to analyse the successful removal of the entire tumour by providing ultra-high resolution and sub-surface image volumes across the surface of the removed tissue.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The funding granted by the CPRIT will support the development of the technology over a three-year project that is expected to ultimately reduce the reoperation rates for breast cancer patients.
During the initial stage of the project, Perimeter intends to train and test the AI algorithms with data collected from the MD Anderson, Baylor College of Medicine, UT Southwestern and UT Health San Antonio pathology labs in Texas.
The company will use specially installed OTIS devices to collect image data of breast tissue samples from approximately 400 patients to develop the software model, using machine learning.
A multi-site pivotal study will be conducted during the second stage to test the new technology against the current standard of care. The study will analyse the impact of technology on the re-operation rate for patients, undergoing breast conservation surgery.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataPerimeter Medical Imaging co-founder and programme director of the grant Andrew Berkeley said: “This CPRIT award is a significant and positive reinforcement to our company and will give us the opportunity to further advance our technology, and perhaps, be the initial push towards new applications in other areas of cancer.
“The award will allow us to hire both clinical and technical expertise and conduct clinical research and trials at internationally recognised cancer care centres throughout the state.”
